永勝醫療(01612.HK):2021年收入減少32.7%至7.78億港元 末期息2.5港仙
格隆匯3月23日丨永勝醫療(01612.HK)發佈2021年全年業績公吿,永勝醫療於年內與一些全球醫療科技集團訂立一系列覆蓋全球市場的多年期協議,將inspiredTM呼吸系統解決方案推向全球。由於去年的基數較高及2019冠狀病毒病患者的住院率下跌,2021年的收入減少32.7%至7.777億港元,符合管理層的預期。
與2019年疫情前的數字相比,該年度收入增加54.9%,呼吸產品分部增加101.5%。骨科支護復康器具分部(上漲25.3%)及成像一次性產品分部(上漲7.2%)錄得穩步增長。該年度毛利為2.591億港元,減少47.6%。公司擁有人應占溢利為6070萬港元,較去年度減少72.0%。倘撇除一次性減值虧損、撇銷及出售一間附屬公司的虧損,公司擁有人應占純利為8960萬港元。宣派2021年末期股息為每股2.5港仙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.